{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:38:52Z","timestamp":1790735932399,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["RGP1\/113\/45"],"award-info":[{"award-number":["RGP1\/113\/45"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bioorg.2025.108247","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T11:54:59Z","timestamp":1738756499000},"page":"108247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Design, synthesis, and molecular dynamics-driven evaluation of quinoline-sulfonamide derivatives as potent and selective EGFR inhibitors with promising anti-cancer efficacy and safety profiles"],"prefix":"10.1016","volume":"157","author":[{"given":"Mahmoud S.","family":"Elkotamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed K.","family":"Elgohary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam A.","family":"Elkelesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Abdelrahman","family":"Alkabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman F.","family":"Khaleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagdy M.","family":"Eldehna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem A.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bioorg.2025.108247_b0005","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.108247_b0010","unstructured":"W.H. Organization, CureAll framework: WHO global initiative for childhood cancer: increasing access, advancing quality, saving lives, (2021)."},{"key":"10.1016\/j.bioorg.2025.108247_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"issue":"39","key":"10.1016\/j.bioorg.2025.108247_b0020","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1021\/acs.jpcb.2c04156","article-title":"Regulation of signaling from the epidermal growth factor family","volume":"126","author":"Burgess","year":"2022","journal-title":"J. Phys. Chem. B"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108247_b0025","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108247_b0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1574887115999201103200248","article-title":"Efficacy and safety of EGFR inhibitors in the treatment of EGFRPositive NSCLC patients: a meta-analysis","volume":"16","author":"Dang","year":"2021","journal-title":"Rev. Recent Clin. Trials"},{"issue":"48","key":"10.1016\/j.bioorg.2025.108247_b0035","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108247_b0040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","article-title":"Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains","volume":"110","author":"Ogiso","year":"2002","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108247_b0045","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108247_b0050","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrc1506","article-title":"Gefitinib\u2014a novel targeted approach to treating cancer","volume":"4","author":"Herbst","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108247_b0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva\u00ae) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2025.108247_b0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108247_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.137554","article-title":"Spiro-fused indoline-quinazoline hybrids as smart bombs against TNF-\u03b1-mediated inflammation","author":"Elkotamy","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108247_b0070","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/molecules29061309","article-title":"Design, synthesis, and biological evaluation of novel phenoxy acetic acid derivatives as selective COX-2 inhibitors coupled with comprehensive bio-pharmacological inquiry, histopathological profiling, and toxicological scrutiny","volume":"29","author":"Alshaye","year":"2024","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108247_b0075","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/ph17020216","article-title":"Design, synthesis and biological assessment of N\u2032-(2-Oxoindolin-3-ylidene)-6-methylimidazo [2, 1-b] thiazole-5-carbohydrazides as potential anti-proliferative agents toward MCF-7 breast cancer","volume":"17","author":"Alshaye","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.108247_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.135010","article-title":"Discovery of new sulfonamide-tethered 2-aryl-4-anilinoquinazolines as the first-in-class dual carbonic anhydrase and EGFR inhibitors","volume":"279","author":"Eldehna","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2025.108247_b0085","doi-asserted-by":"crossref","unstructured":"A. Sabt, M.-H. Abdulla, M.S. Ebaid, J. Pawe\u0142czyk, H.A. Abd El Salam, N.T. Son, N.X. Ha, M.-A. Vaali Mohammed, T. Traiki, A.E. Elsawi, Identification of 2-(N-aryl-1, 2, 3-triazol-4-yl) quinoline derivatives as antitubercular agents endowed with InhA inhibitory activity, Front. Chem. 12 (2024) 1424017.","DOI":"10.3389\/fchem.2024.1424017"},{"key":"10.1016\/j.bioorg.2025.108247_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107703","article-title":"Discovery of new quinoline derivatives bearing 1-aryl-1, 2, 3-triazole motif as influenza H1N1 virus neuraminidase inhibitors","volume":"151","author":"Sabt","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108247_b0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bioorg.2018.10.038","article-title":"Synthesis and anti-proliferative activity of some new quinoline based 4, 5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors","volume":"83","author":"George","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108247_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102985","article-title":"Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors","volume":"89","author":"Abdelsalam","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108247_b0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00686188","article-title":"Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors","volume":"36","author":"Houghton","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108247_b0110","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108247_b0115","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108247_b0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40259-013-0082-x","article-title":"Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"28","author":"Syed","year":"2014","journal-title":"BioDrugs"},{"issue":"17","key":"10.1016\/j.bioorg.2025.108247_b0125","first-page":"4567","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood, J. American Soc. Hematol."},{"issue":"7869","key":"10.1016\/j.bioorg.2025.108247_b0130","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108247_b0135","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108247_b0140","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: first global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.bioorg.2025.108247_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115525","article-title":"Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA\/B) inhibitors: Synthesis, biological evaluation and in silico insights","volume":"28","author":"Al-Sanea","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108247_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113261","article-title":"Discovery of 4-alkoxy-2-aryl-6, 7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity","volume":"215","author":"Elbadawi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108247_b0155","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1080\/14756366.2022.2110869","article-title":"New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies","volume":"37","author":"Elkaeed","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"47","key":"10.1016\/j.bioorg.2025.108247_b0160","doi-asserted-by":"crossref","first-page":"24881","DOI":"10.1039\/C4RA03200D","article-title":"A rhodamine\u2013quinoline based chemodosimeter capable of recognising endogenous OCl\u2212 in human blood cells","volume":"4","author":"Goswami","year":"2014","journal-title":"RSC Adv."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108247_b0165","doi-asserted-by":"crossref","first-page":"14651","DOI":"10.3390\/molecules171214651","article-title":"Synthesis and pharmacological evaluation of novel phenyl sulfonamide derivatives designed as modulators of pulmonary inflammatory response","volume":"17","author":"de Castro Barbosa","year":"2012","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108247_b0170","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1016\/j.ejmech.2009.02.026","article-title":"Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates","volume":"44","author":"de Castro Barbosa","year":"2009","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108247_b0175","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3987\/REV-92-SR4","article-title":"The synthesis of PYRmms, quinolines and other related systems by the vilsmeier and the reverse vilsmeier method","volume":"35","author":"Meth-Cohn","year":"1993","journal-title":"Heterocycles"},{"key":"10.1016\/j.bioorg.2025.108247_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107644","article-title":"Novel imidazo [2, 1-b] thiazoles and imidazo [1, 2-a] pyridines tethered with indolinone motif as VEGFR-2 inhibitors and apoptotic inducers: Design, synthesis and biological evaluations","volume":"151","author":"Elkotamy","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108247_b0185","article-title":"Analysis of cell viability by the MTT assay","volume":"2018","author":"Kumar","year":"2018","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.bioorg.2025.108247_b0190","article-title":"Exploring antitumor activity of novel imidazo [2, 1-b] thiazole and imidazo [1, 2-a] pyridine derivatives on MDA-231 cell line: targeting VEGFR-2 enzyme with computational insight","author":"Elgohary","year":"2024","journal-title":"J. Mol. Struct."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108247_b0195","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/molecules21081013","article-title":"Cytotoxicity, post-treatment recovery, and selectivity analysis of naturally occurring podophyllotoxins from Bursera fagaroides var. fagaroides on breast cancer cell lines","volume":"21","author":"Pe\u00f1a-Mor\u00e1n","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108247_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107766","article-title":"Development of new LSM-83177 analogues as anti-tumor agents against colorectal cancer targeting p53-MDM2 interaction","volume":"153","author":"Elgohary","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108247_b0205","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0300-483X(02)00460-2","article-title":"Cell cycle checkpoint signaling: Cell cycle arrest versus apoptosis","volume":"181","author":"Pietenpol","year":"2002","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108247_b0210","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jhep.2005.02.040","article-title":"Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics","volume":"43","author":"Huether","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2025.108247_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107804","article-title":"Identification of indole-grafted pyrazolopyrimidine and pyrazolopyridine derivatives as new anti-cancer agents: Synthesis, biological assessments, and molecular modeling insights","volume":"153","author":"Eldehna","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2025.108247_b0220","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.3390\/molecules25143230","article-title":"Synthesis and antitumor activity of doxycycline polymeric nanoparticles: Effect on tumor apoptosis in solid ehrlich carcinoma","volume":"25","author":"Gardouh","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108247_b0225","doi-asserted-by":"crossref","first-page":"20974","DOI":"10.1038\/s41598-020-77750-3","article-title":"Identification of potential TNF-\u03b1 inhibitors: from in silico to in vitro studies","volume":"10","author":"Zia","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108247_b0230","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","article-title":"TNF\u03b1 and the TNF receptor superfamily: Structure\u2010function relationship (s)","volume":"50","author":"Idriss","year":"2000","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.bioorg.2025.108247_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.727075","article-title":"Tumor necrosis factor alpha signaling and organogenesis","volume":"9","author":"You","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2025.108247_b0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1019927616000","article-title":"Tumor necrosis factor \u03b1 (TNF-\u03b1)-induced prostaglanding E 2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NF\u03baB in human gingival fibroblasts","volume":"238","author":"Nakao","year":"2002","journal-title":"Mol. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108247_b0245","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.4049\/jimmunol.165.5.2719","article-title":"TNF-\u03b1-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-\u03b32, protein kinase C-\u03b1, tyrosine kinase, NF-\u03baB-inducing kinase, and I-\u03baB kinase 1\/2 pathway","volume":"165","author":"Chen","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2025.108247_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116527","article-title":"A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: Design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments","author":"Hefny","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108247_b0255","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.3390\/molecules28217455","article-title":"New Thiazolyl-Pyrazoline derivatives as potential dual EGFR\/HER2 inhibitors: design, synthesis, anticancer activity evaluation and in silico study","volume":"28","author":"Fakhry","year":"2023","journal-title":"Molecules"},{"issue":"Pt 3","key":"10.1016\/j.bioorg.2025.108247_b0260","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/BJ20121513","article-title":"Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain","volume":"448","author":"Park","year":"2012","journal-title":"Biochem. J"},{"issue":"20","key":"10.1016\/j.bioorg.2025.108247_b0265","doi-asserted-by":"crossref","first-page":"12235","DOI":"10.3390\/ijms232012235","article-title":"Anticoagulants as potential SARS-CoV-2 Mpro inhibitors for COVID-19 patients: in vitro, molecular docking, molecular dynamics, DFT, and SAR studies","volume":"23","author":"Abo Elmaaty","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108247_b0270","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14756366.2021.1885396","article-title":"In silico identification of novel SARS-COV-2 2\u2032-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches","volume":"36","author":"El Hassab","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108247_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111843","article-title":"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine\/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors","volume":"185","author":"Said","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108247_b0280","doi-asserted-by":"crossref","first-page":"11535","DOI":"10.1080\/07391102.2022.2164356","article-title":"Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: Design, synthesis, antiproliferative, docking and MD simulation studies","volume":"41","author":"Taghour","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108247_b0285","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202100719","article-title":"Computational prediction of the potential target of SARS\u2010CoV\u20102 inhibitor plitidepsin via molecular docking, dynamic simulations and MM\u2010PBSA calculations","volume":"19","author":"El Hassab","year":"2022","journal-title":"Chem. Biodivers."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108247_b0290","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2174\/1567201816666190313155117","article-title":"Molecular dynamics simulations of glycyrrhizic acid aggregates as drug-carriers for paclitaxel","volume":"16","author":"Hussain","year":"2019","journal-title":"Curr. Drug Deliv."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108247_b0295","doi-asserted-by":"crossref","first-page":"11674","DOI":"10.3390\/ijms231911674","article-title":"3\u03b2-Corner stability by comparative molecular dynamics simulations","volume":"23","author":"Rudnev","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108247_b0300","article-title":"Synthesis of 1-hydroxy (and 1-alkoxy, 1-acyloxy)-1H-indoles and evaluations of their suppressive activities against tumor growth through inhibiting lactate dehydrogenase A","author":"Cheon","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"W1","key":"10.1016\/j.bioorg.2025.108247_b0305","doi-asserted-by":"crossref","first-page":"W53","DOI":"10.1093\/nar\/gku401","article-title":"ProTox: a web server for the in silico prediction of rodent oral toxicity","volume":"42","author":"Drwal","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108247_b0310","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1016\/j.ejmech.2011.07.007","article-title":"One-pot synthesis of pyrazoline derivatised carbazoles as antitubercular, anticancer agents, their DNA cleavage and antioxidant activities","volume":"46","author":"Taj","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108247_b0315","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70009","article-title":"Molecular docking, DFT and antiproliferative properties of 4\u2010(3, 4\u2010dimethoxyphenyl)\u2212 3\u2010(4\u2010methoxyphenyl)\u2212 1\u2010phenyl\u20101H\u2010pyrazolo [3, 4\u2010b] pyridine as potent anticancer agent with CDK2 and PIM1 inhibition potency","volume":"85","author":"Binjubair","year":"2024","journal-title":"Drug Dev. Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T21:33:06Z","timestamp":1763847186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825001270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":63,"alternative-id":["S0045206825001270"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108247","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and molecular dynamics-driven evaluation of quinoline-sulfonamide derivatives as potent and selective EGFR inhibitors with promising anti-cancer efficacy and safety profiles","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108247"}}